In 2018, Psallidas et al. created and validated a second prognostic scoring system (PROMISE) which included hemoglobin, C-reactive protein, white blood cell count, ECOG, cancer type, pleural fluid TIMP Metallopeptidase inhibitor 1 (TIMP1), and history of previous chemotherapy or radiotherapy. Here, TIMP1 is linked to cancer.